About Regor
Regor is a Healthcare company based in Boston (United States) founded in 2018, and was acquired by Roche in September 2024. Provider of therapeutics related to oncology, autoimmune and metabolic disease. Regor has raised $90 million across 2 funding rounds from investors including Roche, Qilu Pharmaceutical Group and Lilly Asia Ventures. Regor offers products and services including GDC-4198, RGT-075, RGT-419B, and RGT-587. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Regor Therapeutics Group. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Regor was founded in 2018 in Boston, United States, within the biotechnology sector. Therapeutics targeting oncology, autoimmune, and metabolic diseases are developed. A multi-disciplinary computational platform is employed, integrating structural biology, biopharmaceutics, PKPD modeling, and bioinformatics. Drug discovery processes are supported from target identification and lead optimization through to clinical proof of concept, with operations based in the United States.
Products & Services of Regor
Regor offers a comprehensive portfolio of products and services, including GDC-4198, RGT-075, RGT-419B, and RGT-587.
Next-generation inhibitor for breast cancer treatment in clinical trials
Oral small molecule for obesity and type 2 diabetes management
CDK inhibitor for advanced breast cancer patients
Next-gen treatment for breast cancer in phase trials
Funding Insights of Regor
Regor has successfully raised a total of $90M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $90 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90M
- Total Rounds 2
- Last Round Series B — $90M
- Investors Count 6
All 2 funding rounds of Regor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $90M | Series B | – | Lilly Asia Ventures | |
| Jun 2018 | Seed | – | Qilu Pharmaceutical Group | – |
7 investors in total: 7 institutional.
Investors in Regor
Regor has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, Qilu Pharmaceutical Group and Lilly Asia Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mid-market companies are targeted for investment by Loayal Valley Capital. | loyalvalleycapital.com | Shanghai, China | ||
TF Capital is engaged in biotech investment and strategic support. | tfcapital.net | Shanghai, China | ||
| vertexventures.cn | ||||
| lillyasiaventures.com | ||||
Provides advisory services for the medical and health industry. | 2017 | lantingcapital.com | Saanen, Switzerland | |
APIs and intermediates are developed and manufactured for pharmaceuticals. | 1958 | qilu-pharma.com | Jinan, China | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Regor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Regor
19 people are tracked at Regor (14 in leadership, 2 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Xiayang Qiu | Founder CEO | Leadership |
Min Zhong | Chief Operating Officer | Leadership |
Xiaotian Zhu | President of US Operations | Leadership |
Xi Chen | Chief Business Operation | Leadership |
Wenge Zhong | Chief Technology Officer | Leadership |
David J. Valacer | Chief Medical Officer | Leadership |
Julie Xie | Vice President | Leadership |
Mark Pirner | Head, Endocrinology | Leadership |
Andie Zheng | Head, China Development, Clinical | Leadership |
Michael Grimm | Head Of Metabolic Diseases | Leadership |
Lauren Xuan | Director, Public Affairs And Communications | Leadership |
Kurt Riedel | Associate Director Clinical Operations | Leadership |
Larissa | HR Director | Leadership |
Dawn Begley | Associate Clinical Director | Leadership |
Janet Hammond | Scientific Advisor | Board & advisors |
Rikard Holmdahl | Scientific Advisor | Board & advisors |
Hannah Lorden | Associate Clinical Trial Manager | Team |
Yuan Yao | Scientist | Team |
Violet Ting Qiao | Accounting Manager | Team |
Complete people profiles for Regor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Regor
4 dated milestones of Regor across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Regor is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $90.0M.
- Exit Acquired by Roche.
Competitors of Regor
Regor has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Regor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Regor (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Regor
Complete news archive for Regor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regor
Regor was founded in 2018.
Regor is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Regor is a funded company, having raised a total of $90M across 2 funding rounds to date.
Regor was founded in 2018 in Boston, United States, within the biotechnology sector. Therapeutics targeting oncology, autoimmune, and metabolic diseases are developed. A multi-disciplinary computational platform is employed, integrating structural biology, biopharmaceutics, PKPD modeling, and bioinformatics. Drug discovery processes are supported from target identification and lead optimization through to clinical proof of concept, with operations based in the United States.
Regor offers GDC-4198, RGT-075, RGT-419B, and RGT-587.
Regor has 7 investors. Key investors include Roche, Qilu Pharmaceutical Group, Lilly Asia Ventures, Loayal Valley Capital, and LanTing Capital.
Regor operates through Regor Therapeutics Group.
Yes. Regor was acquired by Roche in September 2024.